Richard Brian Rothman

Richard Brian Rothman's AcademicInfluence.com Rankings

Medical

#1882

World Rank

#2263

Historical Rank

Pharmacology

#183

World Rank

#222

Historical Rank

medical Degrees

Richard Brian Rothman

Philosophy

#5565

World Rank

#8403

Historical Rank

Logic

#2822

World Rank

#3880

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Why Is Richard Brian Rothman Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Richard Brian Rothman's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Amphetamine‐type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin (2001) (901)
A proposal for the classification of sigma binding sites. (1992) (706)
Salvinorin A: A potent naturally occurring nonnitrogenous κ opioid selective agonist (2002) (654)
Evidence for Possible Involvement of 5-HT2B Receptors in the Cardiac Valvulopathy Associated With Fenfluramine and Other Serotonergic Medications (2000) (643)
Monoamine transporters and psychostimulant drugs. (2003) (469)
The Designer Methcathinone Analogs, Mephedrone and Methylone, are Substrates for Monoamine Transporters in Brain Tissue (2012) (402)
Depressive-Like Effects of the κ-Opioid Receptor Agonist Salvinorin A on Behavior and Neurochemistry in Rats (2006) (382)
Powerful Cocaine-Like Actions of 3,4-Methylenedioxypyrovalerone (MDPV), a Principal Constituent of Psychoactive ‘Bath Salts’ Products (2013) (373)
Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist. (2002) (298)
N-Desalkylquetiapine, a Potent Norepinephrine Reuptake Inhibitor and Partial 5-HT1A Agonist, as a Putative Mediator of Quetiapine's Antidepressant Activity (2008) (289)
3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. (2003) (286)
Rapid Communication: Attenuation of Methamphetamine‐Induced Neurotoxicity in Copper/Zinc Superoxide Dismutase Transgenic Mice (1994) (272)
3,4-Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: a reappraisal of past and present findings (2006) (251)
N-Substituted Piperazines Abused by Humans Mimic the Molecular Mechanism of 3,4-Methylenedioxymethamphetamine (MDMA, or ‘Ecstasy’) (2005) (245)
An Opioid Agonist that Does Not Induce μ-Opioid Receptor—Arrestin Interactions or Receptor Internalization (2007) (228)
Mu and delta receptors: their role in analgesia in the differential effects of opioid peptides on analgesia. (1982) (215)
Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates. Implications for primary pulmonary hypertension. (1999) (213)
Dose-related neurobehavioral effects of chronic cocaine use. (1999) (209)
Relationship between the Serotonergic Activity and Reinforcing Effects of a Series of Amphetamine Analogs (2005) (190)
SNC 80, a selective, nonpeptidic and systemically active opioid delta agonist. (1995) (189)
Evidence for the Involvement of Dopamine Transporters in Behavioral Stimulant Effects of Modafinil (2009) (187)
Probes for narcotic receptor mediated phenomena. 19. Synthesis of (+)-4-[(alpha R)-alpha-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3- methoxybenzyl]-N,N-diethylbenzamide (SNC 80): a highly selective, nonpeptide delta opioid receptor agonist. (1994) (177)
Distribution of opiate receptor subtypes and enkephalin and dynorphin immunoreactivity in the hippocampus of squirrel, guinea pig, rat, and hamster (1987) (177)
Therapeutic and adverse actions of serotonin transporter substrates. (2002) (175)
In Vitro Characterization of Ephedrine-Related Stereoisomers at Biogenic Amine Transporters and the Receptorome Reveals Selective Actions as Norepinephrine Transporter Substrates (2003) (171)
Endogenous opioids accumulate in plasma in a rat model of acute cholestasis. (1992) (165)
A review of the role of anti‐opioid peptides in morphine tolerance and dependence (1992) (163)
Autoradiographic localization of μ- and δ-opiate receptors in the forebrain of the rat (1986) (156)
Neoclerodane diterpenes as a novel scaffold for mu opioid receptor ligands. (2005) (143)
Interaction of Amphetamines and Related Compounds at the Vesicular Monoamine Transporter (2006) (140)
beta-FNA binds irreversibly to the opiate receptor complex: in vivo and in vitro evidence. (1988) (133)
Interaction of endogenous opioid peptides and other drugs with four kappa opioid binding sites in guinea pig brain (1990) (132)
Opiate receptors in rat pituitary are confined to the neural lobe and are exclusively kappa (1986) (126)
Central mu-opioid receptors are down-regulated in a rat model of cholestasis. (1992) (126)
Allosteric coupling between morphine and enkephalin receptors in vitro. (1982) (125)
Balance between Dopamine and Serotonin Release Modulates Behavioral Effects of Amphetamine‐Type Drugs (2006) (121)
Serotonergic drugs and valvular heart disease (2009) (121)
Labeling by [3H]1,3-di(2-tolyl)guanidine of two high affinity binding sites in guinea pig brain: evidence for allosteric regulation by calcium channel antagonists and pseudoallosteric modulation by sigma ligands. (1991) (117)
Serotonin releasing agents Neurochemical, therapeutic and adverse effects (2002) (117)
GBR12909 antagonizes the ability of cocaine to elevate extracellular levels of dopamine (1991) (113)
High affinity dopamine reuptake inhibitors as potential cocaine antagonists: a strategy for drug development. (1990) (112)
GBR12909 attenuates cocaine-induced activation of mesolimbic dopamine neurons in the rat. (1994) (107)
Locomotor stimulation produced by 3,4-methylenedioxymethamphetamine (MDMA) is correlated with dialysate levels of serotonin and dopamine in rat brain (2008) (106)
Behavioral, biological, and chemical perspectives on atypical agents targeting the dopamine transporter. (2015) (106)
3,4‐methylenedioxymethamphetamine (MDMA) administration to rats decreases brain tissue serotonin but not serotonin transporter protein and glial fibrillary acidic protein (2004) (105)
In Vivo Effects of Amphetamine Analogs Reveal Evidence for Serotonergic Inhibition of Mesolimbic Dopamine Transmission in the Rat (2011) (104)
Effects of phentermine and fenfluramine on extracellular dopamine and serotonin in rat nucleus accumbens: Therapeutic implications (2000) (104)
Visualization of rat brain receptors for the neuropeptide, substance P (1984) (104)
Neuropharmacology of the Naturally Occurring κ-Opioid Hallucinogen Salvinorin A (2011) (103)
Antinociceptive and Hypothermic Effects of Salvinorin A Are Abolished in a Novel Strain of κ-Opioid Receptor-1 Knockout Mice (2006) (102)
Effects of intravenous cocaine on plasma cortisol and prolactin in human cocaine abusers (1995) (101)
Chronic morphine increases μ-opiate receptor binding in rat brain: a quantitative autoradiographic study (1989) (100)
Identification of a primary metabolite of ibogaine that targets serotonin transporters and elevates serotonin. (1995) (99)
Identification of the first trans-(3R,4R)- dimethyl-4-(3-hydroxyphenyl)piperidine derivative to possess highly potent and selective opioid kappa receptor antagonist activity. (2001) (96)
Nonclassical Pharmacology of the Dopamine Transporter: Atypical Inhibitors, Allosteric Modulators, and Partial Substrates (2013) (96)
Methamphetamine-induced serotonin neurotoxicity is mediated by superoxide radicals (1995) (94)
Cocaine reward and MPTP toxicity: alteration by regional variant dopamine transporter overexpression. (1999) (92)
A comparative autoradiographic study of the distributions of substance P and eledoisin binding sites in rat brain (1986) (90)
Salvinorin A analogs as probes in opioid pharmacology. (2008) (90)
Morphine allosterically modulates the binding of [3H]leucine enkephalin to a particulate fraction of rat brain. (1982) (89)
An open-label study of a functional opioid κ antagonist in the treatment of opioid dependence (2000) (89)
Morphine tolerance increases -noncompetative d binding sites? (1986) (88)
Chronic administration of morphine and naltrexone up-regulate mu-opioid binding sites labeled by [3H][D-Ala2,MePhe4,Gly-ol5]enkephalin: further evidence for two mu-binding sites. (1989) (87)
Modulation of ~-mediated antinociception by ~ agonists: characterization with antagonists (1989) (86)
κ2 Opioid Receptors in Limbic Areas of the Human Brain Are Upregulated by Cocaine in Fatal Overdose Victims (1997) (86)
Development of a Rationally Designed, Low Abuse Potential, Biogenic Amine Releaser That Suppresses Cocaine Self-Administration (2005) (83)
Alterations in serotonergic responsiveness during cocaine withdrawal in rats: similarities to major depression in humans (1998) (83)
Neurochemical neutralization of methamphetamine with high‐affinity nonselective inhibitors of biogenic amine transporters: a pharmacological strategy for treating stimulant abuse (2000) (82)
Dopamine transport inhibitors based on GBR12909 and benztropine as potential medications to treat cocaine addiction. (2008) (81)
Superoxide radicals mediate the biochemical effects of methylenedioxymethamphetamine (MDMA): Evidence from using CuZn‐superoxide dismutase transgenic mice (1995) (81)
Effects of Dose and Route of Administration on Pharmacokinetics of (±)-3,4-Methylenedioxymethamphetamine in the Rat (2009) (78)
Monoamine Releasers with Varying Selectivity for Dopamine/Norepinephrine versus Serotonin Release as Candidate “Agonist” Medications for Cocaine Dependence: Studies in Assays of Cocaine Discrimination and Cocaine Self-Administration in Rhesus Monkeys (2007) (76)
Effects of “Legal X” Piperazine Analogs on Dopamine and Serotonin Release in Rat Brain (2003) (76)
Lack of evidence for context-dependent cocaine-induced sensitization in humans: Preliminary studies (1994) (75)
A quantitative study of [3H]D-Ala2-D-Leu5-enkephalin binding to rat brain membranes. Evidence that oxymorphone is a noncompetitive inhibitor of the lower affinity delta-binding site. (1985) (75)
Dual dopamine/serotonin releasers: potential treatment agents for stimulant addiction. (2008) (73)
Cocaine and GBR12909 produce equivalent motoric responses at different occupancy of the dopamine transporter (1992) (72)
Studies of the biogenic amine transporters. IV. Demonstration of a multiplicity of binding sites in rat caudate membranes for the cocaine analog [125I]RTI-55. (1994) (72)
(±)-3,4-Methylenedioxymethamphetamine Administration to Rats Does Not Decrease Levels of the Serotonin Transporter Protein or Alter Its Distribution between Endosomes and the Plasma Membrane (2005) (69)
(+)-Fenfluramine and Its Major Metabolite, (+)-Norfenfluramine, Are Potent Substrates for Norepinephrine Transporters (2003) (68)
Treatment with antisense oligodeoxynucleotide to the opioid δ receptor selectively inhibits δ2-agonist antinociception (1994) (68)
Salvinorin A: Allosteric Interactions at the μ-Opioid Receptor (2007) (68)
Sustained decrease in cocaine-maintained responding in rhesus monkeys with 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-hydroxy-3-phenylpropyl) piperazinyl decanoate, a long-acting ester derivative of GBR 12909. (1996) (67)
Synthesis, opioid receptor binding, and biological activities of naltrexone-derived pyrido- and pyrimidomorphinans. (1999) (67)
Therapeutic potential of monoamine transporter substrates. (2006) (66)
Interaction of the anorectic medication, phendimetrazine, and its metabolites with monoamine transporters in rat brain. (2002) (66)
1-(m-Chlorophenyl)piperazine (mCPP) Dissociates In Vivo Serotonin Release from Long-Term Serotonin Depletion in Rat Brain (2001) (65)
Identification of (3R)-7-hydroxy-N-((1S)-1-[[(3R,4R)-4-(3-hydroxyphenyl)- 3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl)-1,2,3,4-tetrahydro- 3-isoquinolinecarboxamide as a novel potent and selective opioid kappa receptor antagonist. (2003) (64)
Herkinorin analogues with differential beta-arrestin-2 interactions. (2008) (64)
A review of the effects of dopaminergic agents on humans, animals, and drug-seeking behavior, and its implications for medication development (1995) (64)
Identification of a GBR12935 homolog, LR1111, which is over 4,000‐fold selective for the dopamine transporter, relative to serotonin and norepinephrine transporters (1993) (63)
Alterations in the stereochemistry of the kappa-selective opioid agonist U50,488 result in high-affinity sigma ligands. (1989) (63)
Tolerance to 3,4-methylenedioxymethamphetamine in rats exposed to single high-dose binges (2008) (62)
Salvinicins A and B, new neoclerodane diterpenes from Salvia divinorum. (2005) (62)
Probes for narcotic receptor mediated phenomena. 23.1 Synthesis, opioid receptor binding, and bioassay of the highly selective δ agonist (+)-4-[(αR)-α-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-N,N-diethylbenzamide (SNC 80) and related novel nonpeptide δ opioid receptor ligands (1997) (61)
Upregulation of the opioid receptor complex by the chronic administration of morphine: A biochemical marker related to the development of tolerance and dependence (1991) (61)
A comparison of noninternalizing (herkinorin) and internalizing (DAMGO) μ‐opioid agonists on cellular markers related to opioid tolerance and dependence (2007) (60)
Tight binding dopamine reuptake inhibitors as cocaine antagonists (1989) (60)
Characterization of antinociception to opioid receptor selective agonists after antisense oligodeoxynucleotide-mediated "knock-down" of opioid receptor in vivo. (1996) (60)
Autoradiographic evidence for two classes of mu opioid binding sites in rat brain using [125I]FK33824 (1987) (59)
Chronic administration of morphine and naltrexone up-regulate[3H][d-ala2,d-leu5]enkephalin binding sites by different mechanisms (1988) (59)
Evaluation of Phentermine and Fenfluramine, Alone and in Combination, in Normal, Healthy Volunteers (1996) (58)
Dual dopamine/serotonin releasers as potential medications for stimulante and alcohol addictions (2007) (58)
Studies of the Biogenic Amine Transporters. XI. Identification of a 1-[2-[Bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine (GBR12909) Analog That Allosterically Modulates the Serotonin Transporter (2005) (58)
Amphetamine Analogs Increase Plasma Serotonin: Implications for Cardiac and Pulmonary Disease (2006) (58)
Development of novel, potent, and selective dopamine reuptake inhibitors through alteration of the piperazine ring of 1-[2-(diphenylmethoxy)ethyl]-and 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines (GBR 12935 and GBR 12909). (1996) (57)
Allosteric modulation by leucine-enkephalin of [3H]naloxone binding in rat brain. (1981) (57)
Preparation of rat brain membranes greatly enriched with either type-I-delta or type-II-delta opiate binding sites using site directed alkylating agents: Evidence for a two-site allosteric model (1984) (56)
Biosynthesis of dopamine and serotonin in the rat brain after repeated cocaine injections: A microdissection mapping study (1993) (56)
Synthetic studies of neoclerodane diterpenes from Salvia divinorum: semisynthesis of salvinicins A and B and other chemical transformations of salvinorin A. (2006) (56)
Appetite suppressants, cardiac valve disease and combination pharmacotherapy. (2009) (56)
An open-label study of a functional opioid kappa antagonist in the treatment of opioid dependence. (2000) (56)
Region-specific up-regulation of opioid receptor binding in enkephalin knockout mice. (1999) (55)
Doses of GBR12909 that suppress cocaine self‐administration in non‐human primates substantially occupy dopamine transporters as measured by [11C] WIN35,428 PET scans (1999) (55)
In vivo neurobiological effects of ibogaine and its O-desmethyl metabolite, 12-hydroxyibogamine (noribogaine), in rats. (2001) (55)
GBR12909 attenuates amphetamine‐induced striatal dopamine release as measured by [11C]raclopride continuous infusion PET scans (1999) (55)
Development of long-acting dopamine transporter ligands as potential cocaine-abuse therapeutic agents: chiral hydroxyl-containing derivatives of 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine and 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazine. (2002) (54)
The psychotomimetic drug phencyclidine labels two high affinity binding sites in guinea pig brain: evidence for N-methyl-D-aspartate-coupled and dopamine reuptake carrier-associated phencyclidine binding sites. (1989) (54)
High‐dose fenfluramine administration decreases serotonin transporter binding, but not serotonin transporter protein levels, in rat forebrain (2003) (54)
Phentermine/fenfluramine decreases cocaine self‐administration in rhesus monkeys (1997) (53)
Pharmacological examination of trifluoromethyl ring-substituted methcathinone analogs. (2013) (53)
Synthesis of salvinorin A analogues as opioid receptor probes. (2006) (51)
14-Alkoxy- and 14-acyloxypyridomorphinans: μ agonist/δ antagonist opioid analgesics with diminished tolerance and dependence side effects. (2012) (51)
Interaction of psychoactive tryptamines with biogenic amine transporters and serotonin receptor subtypes (2014) (50)
Evidence for alterations in presynaptic serotonergic function during withdrawal from chronic cocaine in rats. (1995) (50)
Interaction of opioid peptides and other drugs with multiple kappa receptors in rat and human brain. Evidence for species differences (1992) (49)
Functional Consequences of Central Serotonin Depletion Produced by Repeated Fenfluramine Administration in Rats (1998) (49)
Identification of Opioid Ligands Possessing Mixed μ Agonist/δ Antagonist Activity among Pyridomorphinans Derived from Naloxone, Oxymorphone, and Hydropmorphone (2004) (49)
Structure-activity relationships for SNC80 and related compounds at cloned human delta and mu opioid receptors. (1996) (49)
Noradrenergic and dopaminergic effects of (+)‐amphetamine‐like stimulants in the baboon Papio anubis (2005) (47)
Synthetic studies of neoclerodane diterpenes from Salvia divinorum: selective modification of the furan ring. (2006) (47)
Synthesis and pharmacological evaluation of 3-(3,4-dichlorophenyl)-1-indanamine derivatives as nonselective ligands for biogenic amine transporters. (2004) (47)
Heteroaromatic analogs of 1-[2-(diphenylmethoxy)ethyl]- and 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines (GBR 12935 and GBR 12909) as high-affinity dopamine reuptake inhibitors. (1997) (46)
Synthetic studies of neoclerodane diterpenes from Salvia divinorum: preparation and opioid receptor activity of salvinicin analogues. (2007) (46)
Persistent antagonism of methamphetamine-induced dopamine release in rats pretreated with GBR12909 decanoate. (2002) (46)
Chronic treatment with phentermine combined with fenfluramine lowers plasma serotonin. (2000) (46)
Opioid peptide receptor studies, 11: Involvement of Tyr148, Trp318 and His319 of the rat μ‐opioid receptor in binding of μ‐selective ligands (1999) (45)
Appetite Suppressants as Agonist Substitution Therapies for Stimulant Dependence (2002) (44)
Behavioural and neurochemical characteristics of phentermine and fenfluramine administered separately and as a mixture in rats (1997) (44)
Low affinity of FMRFamide and four FaRPs (FMRFamide-related peptides), including the mammalian-derived FaRPs F-8-Famide (NPFF) and A-18-Famide, for opioid μ, δ, κ1 , κ2a , or κ2b receptors (1994) (44)
Allosteric Coupling Among Opioid Receptors: Evidence for an Opioid Receptor Complex (1993) (44)
Opioid peptide receptor studies. 12. Buprenorphine is a potent and selective μ/κ antagonist in the [35S]‐GTP‐γ‐S functional binding assay (1999) (43)
Pharmacological activities of optically pure enantiomers of the κ opioid agonist, U50,488, and its cis diastereomer: evidence for three κ receptor subtypes (1989) (43)
Studies of the biogenic amine transporters. II. A brief study on the use of [3H]DA-uptake-inhibition to transporter-binding-inhibition ratios for the in vitro evaluation of putative cocaine antagonists. (1993) (43)
Effect of dopamine receptor antagonists on cocaine subjective effects: a naturalistic case study. (1997) (42)
Chronic intracerebroventricular infusion of the antiopioid peptide, Phe-Leu-Phe-Gln-Pro-Gln-Arg-Phe-NH2 (NPFF), downregulates mu opioid binding sites in rat brain (1993) (42)
Neural and cardiac toxicities associated with 3,4-methylenedioxymethamphetamine (MDMA). (2009) (42)
Oxygenated analogues of 1-[2-(Diphenylmethoxy)ethyl]- and 1-[2-[Bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines (GBR 12935 and GBR 12909) as potential extended-action cocaine-abuse therapeutic agents. (1999) (41)
Dopamine/serotonin releasers as medications for stimulant addictions. (2007) (41)
Identification of an opioid kappa receptor subtype-selective N-substituent for (+)-(3R,4R)-dimethyl-4-(3-hydroxyphenyl)piperidine. (1998) (41)
Evidence for alterations in α2-adrenergic receptor sensitivity in rats exposed to repeated cocaine administration (2004) (39)
Localization of cannabinoid receptors in brain (1988) (39)
Design, synthesis, and monoamine transporter binding site affinities of methoxy derivatives of indatraline. (2000) (39)
Effects of phentermine on responding maintained under multiple fixed-ratio schedules of food and cocaine presentation in the rhesus monkey. (1999) (38)
Potential Drug Abuse Therapeutics Derived from the Hallucinogenic Natural Product Salvinorin A. (2011) (37)
Opioid receptor probes derived from cycloaddition of the hallucinogen natural product salvinorin A. (2011) (37)
Opioid agonist and antagonist antinociceptive properties of [D-Ala2,Leu5,Cys6]enkephalin: selective actions at the deltanoncomplexed site. (1990) (37)
Changes in feeding and locomotion induced by amphetamine analogs in rats. (2009) (36)
Characterization of the enantiomers of cis-N-[2-(3,4-dichlorophenyl)ethyl]-N-methyl-2-(1- pyrrolidinyl)cyclohexylamine (BD737 and BD738): novel compounds with high affinity, selectivity and biological efficacy at sigma receptors. (1992) (36)
Dual dopamine-5-HT releasers: potential treatment agents for cocaine addiction. (2006) (36)
Synthesis and evaluation of N-substituted cis-N-methyl-2-(1-pyrrolidinyl)cyclohexylamines as high affinity sigma receptor ligands. Identification of a new class of highly potent and selective sigma receptor probes. (1990) (36)
Selective Suppression of Cocaine- versus Food-Maintained Responding by Monoamine Releasers in Rhesus Monkeys: Benzylpiperazine, (+)Phenmetrazine, and 4-Benzylpiperidine (2009) (36)
Hybrid dopamine uptake blocker-serotonin releaser ligands: a new twist on transporter-focused therapeutics. (2014) (35)
Synthetic studies of neoclerodane diterpenes from Salvia divinorum: exploration of the 1-position. (2007) (35)
Comparative neuropharmacology of ibogaine and its O-desmethyl metabolite, noribogaine. (2001) (35)
Effect of β-FNA on opiate receptor binding: Preliminary evidence for two types of μ receptors (1983) (35)
Selective and enantiospecific acylation of kappa opioid receptors by (1S,2S)-trans-2-isothiocyanato-N-methyl-N-[2-(1-pyrrolidinyl) cyclohexy l] benzeneacetamide. Demonstration of kappa receptor heterogeneity. (1989) (35)
Probes for narcotic receptor mediated phenomena. 34. Synthesis and structure-activity relationships of a potent mu-agonist delta-antagonist and an exceedingly potent antinociceptive in the enantiomeric C9-substituted 5-(3-hydroxyphenyl)-N-phenylethylmorphan series. (2007) (35)
Enantiomers of diastereomeric cis-N-[1-(2-hydroxy-2-phenylethyl)- 3-methyl-4-piperidyl]-N-phenylpropanamides: synthesis, X-ray analysis, and biological activities. (1995) (34)
Autoradiographic localization of a novel peptide binding site in rat brain using the substance P analog, eledoisin (1984) (34)
Studies of the Biogenic Amine Transporters. 14. Identification of Low-Efficacy “Partial” Substrates for the Biogenic Amine Transporters (2012) (34)
Brain and plasma levels of opioid peptides are altered in rats with thioacetamide-induced fulminant hepatic failure: implications for the treatment of hepatic encephalopathy with opioid antagonists. (1995) (33)
Synthetic studies of neoclerodane diterpenoids from Salvia splendens and evaluation of Opioid Receptor affinity. (2008) (33)
Chronic morphine upregulates a mu-opiate binding site labeled by [3H]cycloFOXY: a novel opiate antagonist suitable for positron emission tomography. (1987) (33)
Uptake and release effects of diethylpropion and its metabolites with biogenic amine transporters. (2000) (33)
Preparation of rat brain membranes highly enriched with opiate kappa binding sites using site-directed acylating agents: Optimization of assay conditions (1985) (33)
Pharmacological characterization of the cloned kappa opioid receptor as a kappa1b subtype (1994) (33)
Differential binding of opioid peptides and other drugs to two subtypes of opioid δ ncx binding sites in mouse brain: Further evidence for δ receptor heterogeneity (1993) (32)
Pharmacological screen for activities of 12-hydroxyibogamine: a primary metabolite of the indole alkaloid ibogaine (1996) (31)
Binding of radiolabeled opiates to slide-mounted sections of molded minced rat brain: A novel method for conducting radioreceptor assays (1983) (31)
Evidence for a Role of Transporter-Mediated Currents in the Depletion of Brain Serotonin Induced by Serotonin Transporter Substrates (2013) (31)
Investigation of the N-substituent conformation governing potency and mu receptor subtype-selectivity in (+)-(3R, 4R)-dimethyl-4-(3-hydroxyphenyl)piperidine opioid antagonists. (1998) (31)
Noribogaine (12‐Hydroxyibogamine): A Biologically Active Metabolite of the Antiaddictive Drug Ibogaine (2000) (30)
Effect of Iboga Alkaloids on µ-Opioid Receptor-Coupled G Protein Activation (2013) (30)
Chronic Fenfluramine Administration Increases Plasma Serotonin (5-Hydroxytryptamine) to Nontoxic Levels (2008) (30)
Further evidence for an opioid receptor complex. (1983) (30)
Preliminary ligand binding data for subtypes of the delta opioid receptor in rat brain membranes. (1991) (30)
Studies of the biogenic amine transporters. VII. Characterization of a novel cocaine binding site identified with [125I]RTI‐55 in membranes prepared from human, monkey and guinea pig caudate (1998) (30)
Downregulation of mu-opioid binding sites following chronic administration of neuropeptide FF (NPFF) and morphine (1996) (30)
Leucine enkephalin noncompetitively inhibits the binding of [3H]naloxone to the opiate mu-recognition site: Evidence for delta←mu binding site interactions in vitro (1985) (29)
Synthesis and transporter binding properties of bridged piperazine analogues of 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine (GBR 12909). (2000) (29)
Evaluation of the conditioned reinforcing effects of phentermine and fenfluramine in the rat: Concordance with clinical studies (1998) (29)
Nonlinear Pharmacokinetics of (±)3,4-Methylenedioxymethamphetamine (MDMA) and Its Pharmacodynamic Consequences in the Rat (2014) (29)
Semisynthetic neoclerodanes as kappa opioid receptor probes. (2012) (28)
Neuroendocrine and neurochemical effects of acute ibogaine administration: a time course evaluation (1996) (28)
An examination of the opiate receptor subtypes labeled by [3H]cyclofoxy: An opiate antagonist suitable for positron emission tomography (1988) (28)
delta Opioid affinity and selectivity of 4-hydroxy-3-methoxyindolomorphinan analogues related to naltrindole. (1999) (28)
Cocaine cross-sensitization to dopamine uptake inhibitors: Unique effects of GBR12909 (1996) (28)
Synthesis, opioid receptor binding, and bioassay of naltrindole analogues substituted in the indolic benzene moiety. (1998) (28)
Autoradiographic localization of mu- and delta-opiate receptors in the forebrain of the rat. (1986) (28)
Studies of the Biogenic Amine Transporters. 13. Identification of “Agonist” and “Antagonist” Allosteric Modulators of Amphetamine-Induced Dopamine Release (2009) (27)
Modulation of mu-mediated antinociception by delta agonists: characterization with antagonists. (1989) (27)
Selective labeling of κ 2 opioid receptors in rat brain by [125I]IOXY: Interaction of opioid peptides and other drugs with multiple κ 2a binding sites (1993) (27)
[3H]1‐[2‐(2‐thienyl)cyclohexyl]piperidine labels two high‐affinity binding sites in human cortex: Further evidence for phencyclidine binding sites associated with the biogenic amine reuptake complex (1991) (27)
Opioid peptide receptor studies. 14. Stereochemistry determines agonist efficacy and intrinsic efficacy in the [35S]GTP‐γ‐S functional binding assay (2001) (27)
Binding of the amphetamine-like 1-phenyl-piperazine to monoamine transporters. (2012) (27)
Alpha-ethyltryptamines as dual dopamine-serotonin releasers. (2014) (27)
Chronic cocaine exposure potentiates prolactin and head shake responses to 5-HT2 receptor stimulation in rats (1996) (26)
Chronic haloperidol treatment up-regulates rat brain PCP receptors. (1987) (26)
Serotonin (5-HT) precursor loading with 5-hydroxy-l-tryptophan (5-HTP) reduces locomotor activation produced by (+)-amphetamine in the rat. (2010) (26)
Probes for narcotic receptor mediated phenomena. 18. Epimeric 6 alpha- and 6 beta-iodo-3,14-dihydroxy-17-(cyclopropylmethyl)-4,5 alpha-epoxymorphinans as potential ligands for opioid receptor single photon emission computed tomography: synthesis, evaluation, and radiochemistry of [125I]-6 beta-iodo- (1992) (26)
Up-regulation of central mu-opioid receptors in a model of hepatic encephalopathy: a potential mechanism for increased sensitivity to morphine in liver failure. (2002) (26)
Treatment of Obesity With “Combination” Pharmacotherapy (2010) (26)
Studies of the Biogenic Amine Transporters. 12. Identification of Novel Partial Inhibitors of Amphetamine-Induced Dopamine Release (2008) (26)
Phentermine and Fenfluramine: Preclinical Studies in Animal Models of Cocaine Addiction (1998) (26)
Importance of phenolic address groups in opioid kappa receptor selective antagonists. (2004) (26)
Acute sensitivity vs. context-specific sensitization to cocaine as a function of genotype (1996) (25)
Phentermine and fenfluramine. Preclinical studies in animal models of cocaine addiction. (1998) (25)
Hypothesis that mesolimbic dopamine (DA) plays a key role in mediating the reinforcing effects of drugs of abuse as well as the rewarding effects of ingestive behaviors. (1994) (25)
Development of Neurochemical Normalization (“Agonist Substitution”) Therapeutics for Stimulant Abuse: Focus on the Dopamine Uptake Inhibitor, GBR12909 (2004) (25)
Design and synthesis of noncompetitive metabotropic glutamate receptor subtype 5 antagonists. (2006) (25)
Synthesis and biological activity of 8beta-substituted hydrocodone indole and hydromorphone indole derivatives. (2002) (25)
Opioid peptide receptor studies. 17. Attenuation of chronic morphine effects after antisense oligodeoxynucleotide knock‐down of RGS9 protein in cells expressing the cloned Mu opioid receptor (2004) (25)
Studies of the biogenic amine transporters. III. Demonstration of two binding sites for [3H]GBR12935 and [3H]BTCP in rat caudate membranes. (1994) (25)
Probes for narcotic receptor mediated phenomena. 15. (3S,4S)-(+)-trans-3-methylfentanyl isothiocyanate, a potent site-directed acylating agent for the delta opioid receptors in vitro. (1989) (25)
A brief study of the selectivity of norbinaltorphimine, (−)-cyclofoxy, and (+)-cyclofoxy among opioid receptor subtypes in vitro (1988) (24)
Endocrine responses during acute nicotine withdrawal (1996) (24)
Probes for narcotic receptor mediated phenomena. Part 28: new opioid antagonists from enantiomeric analogues of 5-(3-hydroxyphenyl)-N-phenylethylmorphan. (2002) (24)
Studies of the biogenic amine transporters. 1. Dopamine reuptake blockers inhibit [3H]mazindol binding to the dopamine transporter by a competitive mechanism: Preliminary evidence for different binding domains (1994) (24)
Identification of a novel “almost neutral” μ‐opioid receptor antagonist in CHO cells expressing the cloned human μ‐opioid receptor (2010) (24)
N-Substituted 9beta-methyl-5-(3-hydroxyphenyl)morphans are opioid receptor pure antagonists. (1998) (24)
Dopamine transporter changes in neuropsychiatric disorders. (1998) (24)
Effects of acute and chronic cocaine on the activity of tuberoinfundibular dopamine neurons in the rat (1993) (24)
Effects of MDMA and related analogs on plasma 5-HT: relevance to 5-HT transporters in blood and brain. (2012) (24)
Synthesis and absolute configuration of optically pure enantiomers of a ϰ‐opioid receptor selective agonist (1987) (23)
Synthesis and biological activity of 3-substituted 3-desoxynaltrindole derivatives. (1998) (23)
Effect of N-alkyl and N-alkenyl substituents in noroxymorphindole, 17-substituted-6,7-dehydro-4,5alpha-epoxy-3,14-dihydroxy-6,7:2',3'-indolomorphinans, on opioid receptor affinity, selectivity, and efficacy. (2001) (23)
Phenylpiperidine opioid antagonists that promote weight loss in rats have high affinity for the κ2B (enkephalin-sensitive) binding site (1993) (23)
Restoration of 3,4-methylenedioxymethamphetamine-induced 5-HT depletion by the administration of l-5-hydroxytryptophan (2007) (23)
Decreased striatal opiate δ-receptors in the rat model of persistent dyskinesia induced by iminodipropionitrile (1986) (23)
Studies of the Biogenic Amine Transporters 15. Identification of Novel Allosteric Dopamine Transporter Ligands with Nanomolar Potency (2015) (22)
A marked change of receptor affinity of the 2-methyl-5-(3-hydroxyphenyl)morphans upon attachment of an (E)-8-benzylidene moiety: synthesis and evaluation of a new class of sigma receptor ligands. (1994) (22)
Neurochemical mechanisms of phentermine and fenfluramine: Therapeutic and adverse effects (2000) (22)
Ligand selectivity of cloned human and rat opioid mu receptors (1995) (21)
Withdrawal from chronic cocaine enhances behavioral sensitivity to the 5-HT2/1C agonist DOI (1993) (21)
Inhibition of MAO-A fails to alter cocaine-induced increases in extracellular dopamine and norepinephrine in rat nucleus accumbens. (2001) (21)
Synthetic studies of neoclerodane diterpenes from Salvia divinorum: role of the furan in affinity for opioid receptors. (2009) (21)
LY164929: a highly selective ligand for the lower affinity [3H]D-Ala2-D-Leu-5-enkephalin binding site (1988) (21)
Methamphetamine Dependence: Medication Development Efforts Based on the Dual Deficit Model of Stimulant Addiction (2000) (21)
Repeated cocaine administration reduces 5-HT1A-mediated prolactin secretion in rats (1995) (20)
Physiological regulation of neurohypophyseal κ-opiate receptors (1988) (20)
Probes for Narcotic Receptor-Mediated Phenomena. 25.1 Synthesis and Evaluation of N-Alkyl-Substituted (α-Piperazinylbenzyl)benzamides as Novel, Highly Selective δ Opioid Receptor Agonists (1997) (20)
Phentermine cardiovascular safety. (2009) (20)
Differential effects of opioid agonists on G protein expression in CHO cells expressing cloned human opioid receptors (2008) (20)
Analysis of binding surfaces: A methodology appropriate for the investigation of complex receptor mechanisms and multiple neurotransmitter receptors (1983) (20)
Abuse-related effects of dual dopamine/serotonin releasers with varying potency to release norepinephrine in male rats and rhesus monkeys. (2014) (20)
Interaction of β‐funaltrexamine with [3H]cycloFOXY binding in rat brain: Further evidence that β‐FNA alkylates the opioid receptor complex (1991) (20)
RTI-4614-4: an analog of (+)-cis-3-methylfentanyl with a 27,000-fold binding selectivity for mu versus delta opioid binding sites. (1991) (20)
Regulation of μ binding sites after chronic administration of antibodies directed against specific anti-opiate peptides (1998) (20)
Interaction of enantiomeric pairs of opiates with phencyclidine binding sites in rat brain: Identification of (+) pentazocine as a ligand potentially suitable for imaging sigma binding sites using positron emission tomography (1988) (20)
PCP site 2: a high affinity MK-801-insensitive phencyclidine binding site. (1994) (20)
(+)-Cis-3-methylfentanyl and its analogs bind pseudoirreversibly to the mu opioid binding site: Evidence for pseudoallosteric modulation (1991) (19)
Alterations in alcohol consumption, withdrawal seizures, and monoamine transmission in rats treated with phentermine and 5‐hydroxy‐L‐tryptophan (2006) (19)
Opioid ligands with mixed properties from substituted enantiomeric N-phenethyl-5-phenylmorphans. Synthesis of a µ-agonist δ-antagonist and δ-inverse agonists (2007) (19)
Specificity of phencyclidine-like drugs and benzomorphan opiates for two high affinity phencyclidine binding sites in guinea pig brain (1990) (19)
Identification and characterization of a novel allosteric modulator (SoRI‐6238) of the serotonin transporter (2004) (19)
Serotonin Transporters, Serotonin Release, and the Mechanism of Fenfluramine Neurotoxicity (2000) (19)
Effects of antihistamines on 3,4‐methylenedioxymethamphetamine‐induced depletion of serotonin in rats (1999) (18)
Synthesis and biological evaluation of 14-alkoxymorphinans. 17. Highly delta opioid receptor selective 14-alkoxy-substituted indolo- and benzofuromorphinans. (2002) (18)
Multidimensional analysis of ligand binding data: Application to opioid receptors (1983) (18)
Serotonin (5‐HT) Transporter Ligands Affect Plasma 5‐HT in Rats (2008) (18)
Probes for narcotic receptor mediated phenomena. 37. Synthesis and opioid binding affinity of the final pair of oxide-bridged phenylmorphans, the ortho- and para-b-isomers and their N-phenethyl analogues, and the synthesis of the N-phenethyl analogues of the ortho- and para-d-isomers. (2008) (18)
Probing the opioid receptor complex with (+)-trans-superfit. I. Evidence that [D-Pen2,D-Pen5]enkephalin interacts with high affinity at the δ cx binding site (1991) (17)
Probes for narcotic receptor mediated phenomena. 26. Synthesis and biological evaluation of diarylmethylpiperazines and diarylmethylpiperidines as novel, nonpeptidic delta opioid receptor ligands. (1999) (17)
Interaction of opioid peptides and other drugs with multiple δ ncx binding sites in rat brain: Further evidence for heterogeneity (1992) (17)
Stimulant sensitization in humans (1997) (17)
Evidence for noncompetitive modulation of substrate‐induced serotonin release (2010) (17)
Preclinical Evaluation of GBR12909 Decanoate as a Long‐Acting Medication for Methamphetamine Dependence (2002) (17)
Methamphetamine and idiopathic pulmonary arterial hypertension: role of the serotonin transporter. (2007) (17)
Evidence that the delta-selective alkylating agent, FIT, alters the mu-noncompetitive opiate delta binding site (1985) (17)
Synthesis of an affinity ligand (‘UPHIT’) for in vivo acylation of the κ‐opioid receptor (1989) (16)
Opioid peptide receptor studies. 1. Identification of a novel δ-opioid receptor binding site in rat brain membranes (1995) (16)
A critical structural determinant of opioid receptor interaction with phenolic 5-phenylmorphans. (2004) (16)
Structure-activity relationship studies of highly selective inhibitors of the dopamine transporter: N-benzylpiperidine analogues of 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine. (2003) (16)
Dual dopamine/serotonin releasers as potential medications for stimulant and alcohol addictions. Chapter 19. (2007) (16)
[3H]cocaine labels a binding site associated with the serotonin transporter in guinea pig brain: Allosteric modulation by paroxetine (1992) (16)
Design and synthesis of promiscuous high-affinity monoamine transporter ligands: unraveling transporter selectivity. (2006) (16)
Effects of methcathinone and 3-Cl-methcathinone (PAL-434) in cocaine discrimination or self-administration in rhesus monkeys. (2013) (16)
Piperidine analogues of 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine (GBR 12909): high affinity ligands for the dopamine transporter. (2002) (16)
The dopamine, serotonin and norepinephrine releasing activities of a series of methcathinone analogs in male rat brain synaptosomes (2018) (16)
Probes for Narcotic Receptor Mediated Phenomena. Part 19. Synthesis of (+)-4-((αR)-α-((2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl)- 3-methoxybenzyl)-N,N-diethylbenzamide (SNC 80): A Highly Selective, Nonpeptide δ Opioid Receptor Agonist. (1994) (16)
Discovery of the First N-Substituted 4β-Methyl-5-(3-hydroxyphenyl)morphan To Possess Highly Potent and Selective Opioid δ Receptor Antagonist Activity (2004) (16)
Synthesis and biological evaluation of tropane-like 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine (GBR 12909) analogues. (2001) (16)
Structure-activity relationships of substituted N-benzyl piperidines in the GBR series: Synthesis of 4-(2-(bis(4-fluorophenyl)methoxy)ethyl)-1-(2-trifluoromethylbenzyl)piperidine, an allosteric modulator of the serotonin transporter. (2006) (15)
Probes for narcotic receptor mediated phenomena. 41. Unusual inverse μ-agonists and potent μ-opioid antagonists by modification of the N-substituent in enantiomeric 5-(3-hydroxyphenyl)morphans. (2011) (15)
Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydropmorphone]. (2004) (15)
Morphine tolerance increases mu-noncompetitive delta binding sites. (1986) (15)
Effect of β‐FNA on Opiate δ Receptor Binding (1984) (15)
Studies of the biogenic amine transporters. VIII: Identification of a novel partial inhibitor of dopamine uptake and dopamine transporter binding (2002) (15)
Open-label pilot study of bupropion plus bromocriptine for treatment of cocaine dependence (2002) (15)
Serotonergic responsiveness in human cocaine users. (2007) (15)
Synthesis and dopamine transporter affinity of chiral 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(2-hydroxypropyl)piperazines as potential cocaine abuse therapeutic agents. (2003) (15)
Upregulation of rat brain opioid receptors by the chronic administration of morphine: possible evidence for an anti-opiate model of tolerance and dependence. (1990) (15)
Studies of the biogenic amine transporters. V. Demonstration of two binding sites for the cocaine analog [125I]RTI-55 associated with the 5-HT transporter in rat brain membranes. (1995) (15)
Endogenous CART peptide regulates mu opioid and serotonin 5-HT2A receptors (2003) (15)
Probing the opioid receptor complex with (+)-trans-SUPERFIT. II. Evidence that μ ligands are noncompetitive inhibitors of the δ cx opioid peptide binding site (1992) (15)
Discovery of an opioid kappa receptor selective pure antagonist from a library of N-substituted 4beta-methyl-5-(3-hydroxyphenyl)morphans. (2002) (15)
Probes for Narcotic Receptor-Mediated Phenomena. 27.1 Synthesis and Pharmacological Evaluation of Selective δ-Opioid Receptor Agonists from 4-[(αR)-α-(2S,5R)-4-Substituted-2,5-dimethyl-1-piperazinyl-3-methoxybenzyl]- N,N-diethylbenzamides and Their Enantiomers (2000) (14)
Treatment with antisense oligodeoxynucleotide to the opioid delta receptor selectively inhibits delta 2-agonist antinociception. (1994) (14)
Synthesis and structural determination of 5H‐benzocyclohepten‐5,8‐imines (1994) (14)
Opioid peptide receptor studies. 10. Nor‐BNI differentially inhibits kappa receptor agonist‐induced G‐protein activation in the guinea pig caudate: Further evidence of kappa receptor heterogeneity (1999) (14)
Opioid peptide receptor studies. 3. Interaction of opioid peptides and other drugs with four subtypes of the κ 2 receptor in guinea pig brain (1995) (14)
Evidence for a μ–δ opioid receptor complex in CHO cells co-expressing μ and δ opioid peptide receptors (2008) (14)
Pharmacological activities of optically pure enantiomers of the kappa opioid agonist, U50,488, and its cis diastereomer: evidence for three kappa receptor subtypes. (1989) (14)
Comparative neurobiological effects of ibogaine and MK-801 in rats. (2000) (14)
Factors influencing agonist potency and selectivity for the opioid delta receptor are revealed in structure-activity relationship studies of the 4-[(N-substituted-4-piperidinyl)arylamino]-N,N-diethylbenzamides. (2001) (14)
Morphine noncompetitively inhibits [3H]leucine enkephalin binding to membranes lacking type-II delta binding sites: Evidence for a two-site allosteric model (1984) (14)
Altered Gene Expression in Pulmonary Tissue of Tryptophan Hydroxylase-1 Knockout Mice: Implications for Pulmonary Arterial Hypertension (2011) (14)
Chronic Morphine Up-Regulates Gα12 and Cytoskeletal Proteins in Chinese Hamster Ovary Cells Expressing the Cloned μ Opioid Receptor (2005) (14)
Synthesis and pharmacological effects of the enantiomers of the N-phenethyl analogues of the ortho and para e- and f-oxide-bridged phenylmorphans. (2008) (14)
Phentermine pretreatment antagonizes the cocaine‐induced rise in mesolimbic dopamine (1996) (14)
Opioid peptide receptor studies. 7. The methylfentanyl congener RTI‐4614‐4 and its four enantiomers bind to different domains of the rat μ opioid receptor (1998) (14)
Low affinity of FMRFamide and four FaRPs (FMRFamide-related peptides), including the mammalian-derived FaRPs F-8-Famide (NPFF) and A-18-Famide, for opioid mu, delta, kappa 1, kappa 2a, or kappa 2b receptors. (1994) (13)
Substituted Amphetamines That Produce Long‐Term Serotonin Depletion in Rat Brain (“Neurotoxicity”) Do Not Decrease Serotonin Transporter Protein Expression (2004) (13)
Safety and Efficacy of Bupropion Combined With Bromocriptine for Treatment of Cocaine Dependence (1996) (13)
Neurotoxicity, drugs of abuse, and the CuZn-superoxide dismutase transgenic mice (1995) (13)
Differential binding of opioid peptides and other drugs to two subtypes of opioid delta ncx binding sites in mouse brain: further evidence for delta receptor heterogeneity. (1993) (13)
(+/-)-4-[(N-allyl-cis-3-methyl-4-piperidinyl)phenylamino]-N,N-diethylbenzamide displays selective binding for the delta opioid receptor. (1999) (13)
Opioid Peptide Receptor Studies. 13. Characterization of Opioid Antagonists with the [35S]-GTP-gamma-S (1998) (12)
Treatment of alcohol and cocaine addiction by the combination of pemoline and fenfluramine: a preliminary case series. (1995) (12)
Evidence for Heterogeneity of Kappa-Opioid Binding Sites: A Review of Data Obtained Using Brain Membranes Depleted of Mu and Delta Binding Sites With Irreversible Agents (1994) (12)
Increased cortical serotonin-2 (5-HT-2) receptors in the iminodipropionitrile (IDPN)-model of persistent dyskinesia in the rat (1987) (12)
Studies of the biogenic amine transporters. VI. Characterization of a novel cocaine binding site, identified with [125I]RTI-55, in membranes prepared from whole rat brain minus caudate. (1995) (12)
Synthesis and opioid activity of enantiomeric N-substituted 2,3,4,4a,5,6,7,7a-octahydro-1H-benzofuro[3,2-e]isoquinolines. (2010) (11)
Synthesis, opioid receptor binding, and functional activity of 5'-substituted 17-cyclopropylmethylpyrido[2',3':6,7]morphinans. (2003) (11)
Tritiated-6-beta-fluoro-6-desoxy-oxymorphone 〈[3H] FOXY〉: a new ligand and photoaffinity probe for the MU opioid receptors (1988) (11)
Tritiated-6-beta-fluoro-6-desoxy-oxymorphone: A highly selective ligand for the opiate mu receptor whose binding is characterized by low nonspecific binding (1984) (11)
Opioid peptide receptor studies. 16. Chronic morphine alters G‐protein function in cells expressing the cloned mu opioid receptor (2003) (11)
Apparent down‐regulation of rat brain μ and κ‐opioid binding sites labelled with [3H]cycloFOXY following chronic administration of the potent 5‐hydroxytryptamine reuptake blocker, clomipramine (1989) (11)
Probes for narcotic receptor-mediated phenomena. 21. Novel derivatives of 3-(1,2,3,4,5,11-hexahydro-3-methyl-2,6-methano-6H-azocino[4,5-b]indol- 6-yl)-phenols with improved delta opioid receptor selectivity. (1996) (11)
Trp284 of the Human δ Opioid Receptor is Required for SNC121 Binding but Not Binding of pCl-DPDPE, Deltorphin II or Naltrindole (1995) (11)
Neurochemical neutralization of amphetamine-type stimulants in rat brain by the indatraline analog (−)-HY038 (2000) (11)
Development of Novel, Potent, and Selective Dopamine Reuptake Inhibitors Through Alteration of the Piperazine Ring of 1-(2-( Diphenylmethoxy)ethyl)- and 1-(2-(Bis(4-fluorophenyl)methoxy)ethyl)-4-( 3-phenylpropyl)piperazines (GBR 12935 and GBR 12909). (2010) (11)
Probes for narcotic receptor mediated phenomena. 17. Synthesis and evaluation of a series of trans-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]benzeneacet amide (U50,488) related isothiocyanate derivatives as opioid receptor affinity ligands. (1990) (11)
(MDMA) Administration to Rats Decreases Brain Tissue Serotonin but not Serotonin Transporter Protein and Glial Fibrillary Acidic Protein (2004) (11)
(E)-8-benzylidene derivatives of 2-methyl-5-(3-hydroxyphenyl)morphans: highly selective ligands for the sigma 2 receptor subtype. (1995) (11)
Ohmefentanyl and Its Stereoisomers: Chemistry and Pharmacology (1997) (11)
Synthetic studies on neoclerodane diterpenes from Salvia splendens: oxidative modifications of ring A. (2009) (10)
DAT/SERT selectivity of flexible GBR 12909 analogs modeled using 3D-QSAR methods. (2007) (10)
[3H]cyclofoxy, a ligand suitable for positron emission tomography, labels mu and kappa opioid receptors (1987) (10)
SoRI 9409, a non-peptide opioid μ receptor agonist/δ receptor antagonist, fails to stimulate [35S]-GTP-γ-S binding at cloned opioid receptors (2001) (10)
Further exploration of 1-[2-[Bis-(4-fluorophenyl)methoxy]ethyl]piperazine (GBR 12909): role of N-aromatic, N-heteroaromatic, and 3-oxygenated N-phenylpropyl substituents on affinity for the dopamine and serotonin transporter. (2003) (10)
A study of the effect of the irreversible delta receptor antagonist [d-Ala2,Leu5,Cys6]Enkephalin on δ cx and δ ncx opioid binding sites in vitro and in vivo (1992) (10)
Design, synthesis, and characterization of 6beta-naltrexol analogs, and their selectivity for in vitro opioid receptor subtypes. (2009) (10)
Discovery of novel peptidic dopamine transporter ligands by screening a positional scanning combinatorial hexapeptide library (1999) (10)
Delta opioid binding selectivity of 3-ether analogs of naltrindole. (1999) (10)
Synthesis of 3-halomethyl-2,3,4,5-tetrahydro-2,5-methano-1H-2-benzazepines and their rearrangement to 4-halo-1,2,3,4,5,6-hexahydro-2,6-methano-2-benzazocines (1993) (9)
Opioid peptide receptor studies. 4. Antisense oligodeoxynucleotide to the delta opioid receptor delineates opioid receptor subtypes (1995) (9)
Intracerebroventricular administration of anti-endothelin-1 IgG selectively upregulates endothelin-A and κ opioid receptors (2004) (9)
Effects of phentermine and fenfluramine on extracellular dopamine and serotonin in rat nucleus accumbens: Therapeutic implications This article is a US Government work and, as such, is in the public domain in the United States of America. (2000) (9)
Stereochemical requirements for pseudoirreversible inhibition of opioid mu receptor binding by the 3‐methylfentanyl congeners, RTI‐46144 and its enantiomers: Evidence for different binding domains (1993) (9)
Endogenous corticotropin releasing factor regulates adrenergic and opioid receptors (2002) (9)
Ignition of Polymers in a Hot Oxidizing Gas (1973) (9)
Probes for narcotic receptor mediated phenomena. 44. Synthesis of an N-substituted 4-hydroxy-5-(3-hydroxyphenyl)morphan with high affinity and selective μ-antagonist activity. (2012) (9)
Cocaine-like discriminative stimulus effects of “norepinephrine-preferring” monoamine releasers: time course and interaction studies in rhesus monkeys (2017) (9)
Cross-linking of [125I]-endorphin to -opioid receptors during development (1989) (9)
Regulation of the rat brain endothelin system by endogenous β-endorphin (2006) (9)
Effects of phentermine and cocaine on fenfluramine-induced depletion of serotonin in mouse brain. (1996) (9)
Unexpectedly high levels of opioid peptides in rat brain membranes (1987) (9)
Opioid Peptide Receptor Studies. 6. The 3-Methylfentanyl Congeners RTI-4614-4 and Its Enantiomers Differ in Efficacy, Potency, and Intrinsic Efficacy as Measured by Stimulation of [35S]GTP-γ-S Binding Using Cloned μ-Opioid Receptors (1997) (9)
Resolution of two [35S]GTP-γ-S binding sites and their response to chronic morphine treatment: A binding surface analysis (2000) (8)
Neurochemical and Neuroendocrine Effects of Ibogaine in Rats: Comparison to MK‐801 (1998) (8)
Probes for narcotic receptor mediated phenomena. Part 42: synthesis and in vitro pharmacological characterization of the N-methyl and N-phenethyl analogues of the racemic ortho-c and para-c oxide-bridged phenylmorphans. (2011) (8)
The potent opioid agonist, (+)-cis-3-methylfentanyl binds pseudoirreversibly to the opioid receptor complex in vitro and in vivo: evidence for a novel mechanism of action. (1990) (8)
Design and synthesis of 2- and 3-substituted-3-phenylpropyl analogs of 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine and 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazine: role of amino, fluoro, hydroxyl, methoxyl, methyl, methylene, and oxo substituents on affinity fo (2008) (8)
Binding surface analysis: an intuitive yet quantitative method for the design and analysis of ligand binding studies. (1985) (8)
Probes for narcotic receptor mediated phenomena. 39. Enantiomeric N-substituted benzofuro[2,3-c]pyridin-6-ols: synthesis and topological relationship to oxide-bridged phenylmorphans. (2009) (8)
Probes for narcotic receptor-mediated phenomena. 20. Alteration of opioid receptor subtype selectivity of the 5-(3-hydroxyphenyl)morphans by application of the message-address concept: preparation of delta-opioid receptor ligands. (1995) (8)
Pretreatment of rats with the irreversible μ-receptor antagonist, β-FNA, fails to prevent naltrexone-induced upregulation of μ-opioid receptors (1990) (8)
Chronic exposure to antibodies directed against anti-opiate peptides alter δ-opioid receptor levels (1999) (7)
Libraries of opiate and anti-opiate peptidomimetics containing 2,3-methanoleucine. (1997) (7)
Combined phentermine/fenfluramine administration and central serotonin neurons (1998) (7)
Opioid Peptide Receptor Studies. 8. One of the Mouse Brain δNCX Binding Sites is Similar to the Cloned Mouse Opioid δ Receptor: Further Evidence for Heterogeneity of δ Opioid Receptors (1998) (7)
Identification of a novel partial inhibitor of dopamine transporter among 4-substituted 2-phenylquinazolines. (2002) (7)
Perinatal lead exposure alters locomotion induced by amphetamine analogs in rats. (2011) (7)
Erratum: Identification of Opioid Ligands Possessing Mixed μ Agonist/δ Antagonist Activity among Pyridomorphinans Derived from Naloxone, Oxymorphone, and Hydromorphone (Journal of Medicinal Chemistry (2004) 47 (1400)) (2004) (7)
Discovery of the first N-substituted 4beta-methyl-5-(3-hydroxyphenyl)morphan to possess highly potent and selective opioid delta receptor antagonist activity. (2004) (7)
Optically pure (-)-4-[(N-allyl-3-methyl-4-piperidinyl)phenyl-amino]-N,N-diethylbenzami de displays selective binding and full agonist activity for the delta opioid receptor. (1999) (7)
Probes for narcotic receptor mediated phenomena. 43. Synthesis of the ortho-a and para-a, and improved synthesis and optical resolution of the ortho-b and para-b oxide-bridged phenylmorphans: compounds with moderate to low opioid-receptor affinity. (2011) (7)
In vitro and in vivo assessment of mu opioid receptor constitutive activity. (2010) (6)
A study of the interaction of the alkylating agent, NIH10236, with opioid receptors in vitro and in vivo (1989) (6)
Probes for narcotic receptor mediated phenomena. 46. N-substituted-2,3,4,9,10,10a-hexahydro-1H-1,4a-(epiminoethano)phenanthren-6- and 8-ols - carbocyclic relatives of f-oxide-bridged phenylmorphans. (2012) (6)
In Vivo Correlates of Central Serotonin Function after High‐Dose Fenfluramine Administration (1998) (6)
Ionic conditions differentially affect 3H-DADL binding to type-I and type-II opiate delta receptors in vitro (1984) (6)
RE: Pulmonary Hypertension Associated with Use of Phentermine? (2011) (6)
Does phentermine inhibit monoamine oxidase? (1999) (6)
Derivatives of 17-(2-methylallyl)-substituted noroxymorphone: variation of the delta address and its effects on affinity and selectivity for the delta opioid receptor. (2001) (6)
Evidence for four opioid kappa binding sites in guinea pig brain. (1990) (6)
Probes for narcotic receptor mediated phenomena. 40. N-substituted cis-4a-ethyl-1,2,3,4,4a,9a-hexahydrobenzofuro[2,3-c]pyridin-8-ols. (2010) (6)
Opioid peptide receptor studies. 15. Relative efficacy of 4‐[(N‐allyl‐3‐methyl‐4‐piperidinyl)phenylamino]‐N,N‐diethylbenzamide and related compounds at the cloned human δ‐opioid receptor (2001) (6)
Interaction of leucine enkephalin with (3H)naloxone binding in rat brain: Evidence for an opioid receptor complex (1983) (6)
The age-adjusted mortality rate from primary pulmonary hypertension, in age range 20 to 54 years, did not increase during the years of peak "phen/fen" use. (2000) (6)
Effect of beta-FNA on opiate receptor binding: preliminary evidence for two types of mu receptors. (1983) (5)
ALTERATIONS IN THE BINDING OF [3H]LEUCINE‐ENKEPHALIN TO STRIATAL MEMBRANES BY ENDOGENOUS FACTORS (1979) (5)
Antisense oligodeoxynucleotide to the cloned delta opioid receptor selectively inhibits supraspinal, but not spinal, antinociceptive effects of [D-Ala2, Glu4]deltorphin (1994) (5)
RTI‐4793‐14, a new ligand with high affinity and selectivity for the (+)‐MK801‐insensitive [3H]1‐[1‐(2 thienyl)cyclohexyl]piperidine binding site (PCP site 2) of guinea pig brain (1994) (5)
N-substituted octahydro-4a-(3-hydroxyphenyl)-10a-methyl-benzo[g]isoquinolines are opioid receptor pure antagonists. (1998) (5)
Wash-resistant inhibition of phencyclidine- and haloperidol-sensitive sigma receptor sites in guinea pig brain by putative affinity ligands: Determination of selectivity (1990) (5)
Diaryldimethylpiperazine ligands with μ- and δ-opioid receptor affinity: Synthesis of (+)-4-[(αR)-α-(4-allyl-(2S, 5S)-dimethylpiperazin-1-yl)-(3-hydroxyphenyl)methyl]- N-ethyl-N-phenylbenzamide and (-)-4-[(αR)-α-(2S, 5S)-dimethylpiperazin-1-yl)-(3-hydroxyphenyl)methyl]-N-ethyl-N -phenylbenzamide (2003) (5)
Synthesis and Absolute Configuration of Chiral Piperazines Related to GBR-12909 as Dopamine Reuptake Inhibitors (1994) (5)
Is phentermine an inhibitor of monoamine oxidase? A critical appraisal (1999) (5)
Opioid ligands with mixed properties from substituted enantiomeric N-phenethyl-5-phenylmorphans. Synthesis of a micro-agonist delta-antagonist and delta-inverse agonists. (2007) (5)
Selective labeling of kappa 2 opioid receptors in rat brain by [125I]IOXY: interaction of opioid peptides and other drugs with multiple kappa 2a binding sites. (1993) (5)
Novel ligands for the opioid receptors: synthesis and structure-activity relationships among 5'-aryl and 5'-heteroaryl 17-cyclopropylmethyl-4,5 alpha-epoxypyrido[2',3':6,7]morphinans. (2003) (5)
Serotonin-4 receptor antagonists reverse cocaine-induced cardiac arrhythmia. (1998) (5)
Studies of the biogenic amine transporters. 10. Characterization of a novel cocaine binding site in brain membranes prepared from dopamine transporter knockout mice (2002) (5)
Anorexogen-Related Cardiac Valvulopathy (2002) (4)
Interrogating the Activity of Ligands at Monoamine Transporters in Rat Brain Synaptosomes (2016) (4)
Neurochemical and neuroendocrine effects of ibogaine in rats: comparison to MK-801. (1998) (4)
4-[(8-Alkyl-8-azabicyclo[3.2.1]octyl-3-yl)-3-arylanilino]-N,N-diethylbenzamides: high affinity, selective ligands for the delta opioid receptor illustrate factors important to antagonist activity. (2000) (4)
Opioid peptide receptor studies. 9. Identification of a novel non-μ- non-δ-like opioid peptide binding site in rat brain (1998) (4)
High-performance liquid chromatographic resolution of synthetic opiate and "anti-opiate" peptides from human plasma. (1995) (4)
Pseudoallosteric modulation by (+)-MK801 of NMDA-coupled phencyclidine binding sites. (1990) (4)
Synthesis and Structure-Activity Relationships of a Potent μ-Agonist δ-Antagonist and an Exceedingly Potent Antinociceptive in the Enantiomeric C 9-Substituted 5-( 3-Hydroxyphenyl )-N-phenylethylmorphan Series (4)
[3H]1,3-Di(2-tolyl)guanidine labels two high affinity binding sites in guinea pig brain: evidence for allosteric regulation by calcium channel blockers and sigma ligands. (1990) (4)
Opioid Peptide Receptor Studies. 13. Characterization of Opioid Antagonists With the [35S]GTP-γ-S Binding Assay (1999) (4)
Upregulation of the mu-noncompetitive delta binding site by chronic morphine administration: effect of preincubating membranes in 400 nM sodium chloride. (1986) (4)
SoRI 9409, a non-peptide opioid mu receptor agonist/delta receptor antagonist, fails to stimulate [35S]-GTP-gamma-S binding at cloned opioid receptors. (2001) (4)
MPTP lesions of the nigrostriatal dopaminergic projection decrease [3H]1-[1-(2-thienyl)cyclohexyl]-piperidine binding to PCP site 2: Further evidence that PCP site 2 is associated with the biogenic amine reuptake complex (1992) (4)
Novel Opioid Antagonists with Mixed/Dual Selectivity (2009) (4)
A review of the effects of dopaminergic agents in humans: implications for medication development. (1994) (4)
Probes for narcotic receptor mediated phenomena. 23. Synthesis, opioid receptor binding, and bioassay of the highly selective delta agonist (+)-4-[(alpha R)-alpha-((2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]- N,N-diethylbenzamide (SNC 80) and related novel nonpeptide delta opioid re (1997) (4)
Chronic iminodipropionitrile (IDPN) causes no changes in the rat brain phencyclidine (PCP) receptor (1986) (4)
Effects of electroconvulsive shock on the retention of cocaine-induced conditioning (1994) (4)
Interaction of beta-funaltrexamine with [3H]cycloFOXY binding in rat brain: further evidence that beta-FNA alkylates the opioid receptor complex. (1991) (4)
Targeted screening for biogenic amine transporters: potential applications for natural products. (2005) (4)
[3H]SNC121: A novel high affinity ligand for rat brain delta receptors: Preliminary studies (1994) (4)
A study of the effect of the irreversible delta receptor antagonist [D-Ala2,Leu5,Cys6]-enkephalin on delta cx and delta ncx opioid binding sites in vitro and in vivo. (1992) (3)
An efficient synthesis of 3-OBn-6β,14-epoxy-bridged opiates from naltrexone and identification of a related dual MOR inverse agonist/KOR agonist. (2012) (3)
Interaction of naloxone with the opioid receptor complex in vitro (1982) (3)
Preliminary evidence that the high affinity dopamine reuptake inhibitor, GBR12909, antagonizes the ability of cocaine to elevate extracellular levels of dopamine. (1990) (3)
A postmortem study of the effect of chronic opiate abuse on psychotomimetic binding sites of human frontal cortex (1987) (3)
Treatment of a 4-year-old boy with ADHD with the dopamine releaser phentermine. (1996) (3)
Probes for narcotic receptor mediated phenomena. 47. Novel C4a- and N-substituted-1,2,3,4,4a,9a-hexahydrobenzofuro[2,3-c]pyridin-6-ols. (2013) (3)
Enantiomers of (¤)-cis-N-[1-(2-Hydroxy-2-phenylethyl)-3-methyl-4-piperidyl]-N-phenylpropanamide: Influence of the Hydroxyl Group (1991) (3)
Mu-Delta Interactions In Vitro and In Vivo (2003) (3)
TDIQ (5,6,7,8-tetrahydro-1,3-dioxolo[4,5-g]isoquinoline) inhibits the consumption of “snacks” in mice (2006) (3)
The Effect of FMRFamide Analogs on [35S]GTP-γ-S Stimulation in Squid Optic Lobes (1998) (3)
Probes for narcotic receptor mediated phenomena. 48. C7- and C8-substituted 5-phenylmorphan opioids from diastereoselective alkylation. (2013) (3)
Multiple opioid receptors: An examination of the dissociation of [3H]leucine enkephalin from rat brain membranes (1983) (2)
Opioid Peptide Receptor Studies. 5. Further Evidence That the Methylfentanyl Congener RTI-4614-4 and Its Four Stereoisomers Bind to Different Domains of the Rat Mu-Opioid Receptor (1995) (2)
The biogenic amine transporter activity of vinylogous amphetamine analogs (2016) (2)
Erratum: Chronic treatment with phentermine combined with fenfluramine lowers plasma cholesterol (American Journal of Cardiology (April 1, 2000) 85 (913-915)) (2000) (2)
An electrophilic affinity ligand based on (+)-MK801 distinguishes PCP site 1 from PCP site 2 (1994) (2)
Identification of novel allosteric dopamine transporter ligands with nanomolar potency (2015) (2)
Opioid peptide receptor studies. 8. One of the mouse brain deltaNCX binding sites is similar to the cloned mouse opioid delta receptor: further evidence for heterogeneity of delta opioid receptors. (1998) (2)
Neurobiology of 3,4-Methylenedioxymethamphetamine (MDMA, or ""Ecstasy"") (2007) (2)
Characterization of NMDA-coupled and dopamine reuptake carrier coupled [3H]-TCP binding sites in guinea pig brain. (1989) (2)
Regulation of the rat brain endothelin system by endogenous beta-endorphin. (2006) (2)
Synthesis of an affinity ligand ('UPHIT') for in vivo acylation of the kappa-opioid receptor. (1989) (2)
Opioid Peptide Receptor Studies 2. [3H]SNC-121, a Novel, Selective, and High-Affinity Ligand for Opioid Delta Receptors (1995) (2)
Studies of the biogenic amine transporters. 10. Characterization of a novel cocaine binding site in brain membranes prepared from dopamine transporter knockout mice. (2002) (2)
Synthesis and Biological Activity of 8β‐Substituted Hydrocodone Indole and Hydromorphone Indole Derivatives. (2002) (2)
Chronic I.C.V. infusion with monoclonal anti-NPFF IgG up-regulates mu opioid binding sites in rat brain: An autoradiographic study (1994) (2)
Salvinorin A Analogues as Probes in Opioid Pharmacology (2008) (2)
Pharmacological properties of (+)-buprenorphine and (+)-diprenorphine. (1990) (2)
The effect of FMRFamide analogs on [35S]GTP-gamma-S stimulation in squid optic lobes. (1998) (2)
Novel kappa opioid receptor and sigma ligands. (1992) (2)
Synthesis and Ligand Binding at PCP Sites 1 and 2 for Hexahydro-2-substituted-1-methylindeno[1,2-b]pyrroles (1992) (2)
Opportunities for Medication Development in Obesity (2000) (2)
6.07 – Addiction (2007) (1)
Probes for narcotic receptor mediated phenomena 49. N-substituted rac-cis-4a-arylalkyl-1,2,3,4,4a,9a-hexahydrobenzofuro[2,3-c]pyridin-6-ols. (2015) (1)
Pseudoallosteric modulation by (+)-MK801 of NMDA (N-methyl-D-aspartate)-coupled phencyclidine binding sites (1990) (1)
Intracerebroventricular administration of superFIT and its enantiomer to rats: Evidence for in vivo acylation of [3H]DADL binding sites (1987) (1)
The competitive NMDA receptor antagonist, CPP, allosterically modulates NMDA receptor associated PCP binding sites in the absence of steric hinderance. (1990) (1)
BW373U86, its enantiomers, and related compounds: Interactions of non-peptide delta agonists at multiple δ cx binding sites in rat brain (1994) (1)
Synthesis and Structural Determination of 5H‐Benzocyclohepten‐5,8‐ imines (1995) (1)
Phentermine cardiovascular safety. In response to Yosefy C, Berman M, Beeri R. Cusp tear in bicuspid aortic valve possibly caused by phentermine. International journal of cardiology 2006;106:262-3. (2010) (1)
[125]RTI-55, a high affinity cocaine analog, labels two binding sites in human caudate membranes possibly related to the 5-HT transporter (1994) (1)
Evidence that GBR12909 attenuates dopaminergic actions of cocaine by binding to dopamine transporter sites in rat brain (1995) (1)
Diaryldimethylpiperazine ligands with mu- and delta-opioid receptor affinity: Synthesis of (+)-4-[(alphaR)-alpha-(4-allyl-(2S,5S)-dimethylpiperazin-1-yl)-(3-hydroxyphenyl)methyl]-N-ethyl-N-phenylbenzamide and (-)-4-[(alphaR)-alpha-(2S,5S)-dimethylpiperazin-1-yl)-(3-hydroxyphenyl)methyl]-N-ethyl-N-ph (2003) (1)
Rat brain PCP receptors: Alterations in binding parameters following chronic administration of opiate agonists and antagonists (1987) (1)
Kappa Opioid Receptor Ligands Derived from Salvinorin A (2008) (1)
The affinity ligand "UPHIT" acylates kappa opioid binding sites in vivo. (1990) (1)
6β‐[125Iodo]‐3, 14‐dihydroxy‐17‐methyl‐4, 5α‐epoxymorphinan ([125I]IOXY‐AGO): A potent and selective radioligand for opioid μ receptors (1995) (1)
In vivo correlates of central serotonin function after high-dose fenfluramine administration. (1998) (1)
STIMULANT SENSITIZATION IN HUMANS. AUTHORS' REPLY (1997) (1)
Cross-linking of [125I]beta-endorphin to mu-opioid receptors during development. (1989) (1)
A study of bile acids as opioid receptor ligands in rat brain membranes (2004) (1)
Evidence for high and low affinity [3H]cocaine binding sites associated with the serotonin reuptake complex in guinea pig brain: allosteric modulation by paroxetine. (1990) (1)
Probes for narcotic receptor-mediated phenomena. 27. Synthesis and pharmacological evaluation of selective delta-opioid receptor agonists from 4-[(alphaR)-alpha-(2S,5R)-4-substituted-2, 5-dimethyl-1-piperazinyl-3-methoxybenzyl]-N,N-diethylbenzamides and their enantiomers. (2000) (1)
The dopamine, serotonin and norepinephrine releasing activities of a series of methcathinone analogs in male rat brain synaptosomes (2018) (1)
Modulation of Guanosine-5′- O -(3-[ 35 S]thio)triphosphate ([ 35 S]GTP-γ-S) Binding by Opioid Agonists and Antagonists (2003) (1)
In vivo binding of (+)-cis methylfentanyl at the opiate receptor complex and behavioral correlates: evidence for a novel mechanism of action. (1989) (1)
Physiological regulation of neurohypophyseal kappa-opiate receptors. (1988) (1)
Biological Evaluation of Diarylmethylpiperazines and Diarylmethylpiperidines as Novel, Nonpeptidic ‰ Opioid Receptor Ligands (2000) (0)
Trifluoromethyl ring‐substituted methcathinone analogs: activity at monoamine uptake transporters (2011) (0)
Novel Opioids Based on Salvinorin A (2008) (0)
In vivo evidence that extracellular serotonin inhibits dopaminergic effects of monoamine releasing agents in the rat (2004) (0)
Phentermine cardiovascular safety II: response to Yosefy Int J Cardiol. 2009 Epub Mar 19. (2010) (0)
Preliminary evidence that CBR12909 is less effective at elevating mesolimbic dopamine function than cocaine (1991) (0)
An Efficient Synthesis of 3‐OBn‐6β,14‐Epoxy‐Bridged Opiates from Naltrexone and Identification of a Related Dual MOR Inverse Agonist/KR Agonist. (2013) (0)
Effect of beta-FNA on opiate delta receptor binding. (1984) (0)
TREATING OBESITY AND FOOD CRAVING (2017) (0)
Optically Pure (-)-4-[(N-Allyl-3-methyl-4-piperidinyl)phenylamino] -N,N-diethylbenzamide Displays Selective Binding and Full Agonist Activity for the δ Opioid Receptor. (2000) (0)
Synthesis of 3-Halomethyl-2,3,4,5-tetrahydro-2,5-methano-1H-2- benzazepines and Their Rearrangement to 4-Halo-1,2,3,4,5,6-hexahydro-2, 6-methano-2-benzazocines. (1993) (0)
Association of subarachnoid hemorrhage and phentermine usage: Coincidence, not causation. (2015) (0)
Synthesis of [3H]‐labelled 4‐[Ethyl[2,5,6‐trimethyl‐7‐(2,4,6‐trimethylphenyl)pyrrolo[2,3‐d]pyrimidin‐4‐yl]amino]‐2,3‐[3H]‐butan‐1‐ol: a high affinity radioligand for the corticotropin‐releasing hormone type 1 receptor (2006) (0)
4‐[(8‐Alkyl‐8‐azabicyclo [3.2.1]octyl‐3‐yl)‐3‐arylanilino]‐N,N‐diethylbenzamides: High Affinity, Selective Ligands for the Delta Opioid Receptor Illustrate Factors Important to Antagonist Activity. (2000) (0)
Slowly dissociating (tight binding) dopamine, serotonin or norepinephrine reuptake inhibitors as cocaine antagonists. (1990) (0)
Smoking cessation in a patient being treated with fenfluramine plus phentermine for simple obesity. (1996) (0)
Effects of ibogaine on neurohormones and neurotransmitter systems in rat (1996) (0)
Delta Opioid Binding Selectivity of 3-Ether Analogues of Naltrindole. (2000) (0)
Evidence that the anorectic agents, phendimetrazine and diethylpropion, are prodrugs (2001) (0)
Novel κ-opioid Receptor Antagonists Derived from Salvinorin A (2007) (0)
Does phentermine inhibit monoamine oxidase? (multiple letters) [4] (1999) (0)
Interaction of psychoactive tryptamines with biogenic amine transporters and serotonin receptor subtypes (2014) (0)
Cocaine-like discriminative stimulus effects of “norepinephrine-preferring” monoamine releasers: time course and interaction studies in rhesus monkeys (2017) (0)
Probes for Narcotic Receptor-Mediated Phenomena. Part 21. Novel Derivatives of 3-(1,2,3,4,5,11-Hexahydro-3-methyl-2,6-methano-6H- azocino(4,5-b)indol-6-yl)phenols with Improved δ Opioid Receptor Selectivity. (1996) (0)
Chronic cocaine abuse is associated with peripheral nerve damage (1994) (0)
Probes for narcotic receptor mediated phenomena 22. (1) synthesis and characterization of optically pure [3H](+)-4-[(αR)-α-((2S, 5R)-4-propyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-N, N-diethylbenzamide, [3H]SNC 121, a novel high affinity and select (1996) (0)
Pretreatment of rats with the irreversible mu-receptor antagonist, beta-FNA, fails to prevent naltrexone-induced upregulation of mu-opioid receptors. (1990) (0)
Derivatives of 17‐(2‐Methylallyl)‐substituted Noroxymorphone: Variation of the Delta Address and Its Effects on Affinity and Selectivity for the Delta Opioid Receptor. (2002) (0)
The case of posterior reversible encephalopathy with intracranial hemorrhage was likely due to uncontrolled hypertension, and was unrelated and coincidental to long-term phentermine use. (2015) (0)
Identification of a Novel Partial Inhibitor of Dopamine Transporter Among 4-Substituted 2-Phenylquinazolines (2002) (0)
Dexamethasone To Prevent Postbronchoscopy Fever in Children (2007) (0)
Synthesis of Heterocyclic Analogues of Salvinorin A (2006) (0)
Preparation of Ring D Modified Analogues of Salvinorin A and Evaluation of Their Activity at Opioid Receptors (2006) (0)
Amide Analogs of (¤)-cis-N-[1-(2-hydroxy-2-phenylethyl)-3-methyl-4-piperidyl]-N-phenylpropanamide: Highly Selective Ligands for the Mu Opioid Binding Site (1991) (0)
Salvinicins A (I) and B (II), New Neoclerodane Diterpenes from Salvia divinorum. (2005) (0)
Site-directed affinity ligands as tools to study the phenomenology and mechanisms of morphine-induced upregulation of opioid receptors. (1989) (0)
[125I]IOXY-AGO: A high affinity, mu-selective agonist opioid receptor ligand (1994) (0)
Pharmacology of “next generation” synthetic cathinones: The future is now (2015) (0)
Characterization of enantiomers of (±)BW373U86 and related compounds: Highly selective non-peptidic delta opioid agonists (1994) (0)
Synthetic Modifications of the Furan Ring of Salvinorin A, a Neoclerodane Diterpene from Salvia divinorum (2006) (0)
Chemical modifications to alter monoamine releasing activity of phenmetrazine analogs as potential treatments of stimulant addiction (2015) (0)
Synthesis and Transporter Binding Properties of Bridged Piperazine Analogues of 1-{2-[Bis(4-fluorophenyl)methoxy]ethyl}-4-(3-phenylpropyl)piperazine (GBR 12909). (2001) (0)
Withdrawal from chronic cocaine is associated with changes in presynaptic serotonergic function in rats (1994) (0)
Neuropharmacology of replacement analogs of the designer drug 3,4-methylenedioxymethcathinone (2015) (0)
JPET # 101618 2 RUNNING TITLE PAGE Running Title : Amphetamines increase plasma serotonin (2006) (0)
(.+-.)-4-[(N-Allyl-cis-3-methyl-4-piperidinyl)phenylamino] -N,N-diethylbenzamide Displays Selective Binding for the Delta Opioid Receptor. (2010) (0)
Opioid peptide receptor studies. 9. Identification of a novel non-mu- non-delta-like opioid peptide binding site in rat brain. (1998) (0)
Synthesis, Opioid Receptor Binding, and Functional Activity of 5′‐Substituted 17‐Cyclopropylmethylpyrido[2′,3′:6,7]morphinans. (2003) (0)
( (cid:1) )-Fenfluramine and Its Major Metabolite, ( (cid:1) )-Norfenfluramine, Are Potent Substrates for Norepinephrine Transporters (2003) (0)
veterans with PTSD and alcohol use disorder (2015) (0)
Retraction and Apology: Is Phentermine an Inhibitor of Monoamine Oxidase? (1999) (0)
Dihydrocodeinone-hydrazone, dihydrocodeinone-oxime, naloxone-3-ome-oxime, and clocinnamox fail to irreversibly inhibit opioid kappa receptor binding (1994) (0)
Dopamine re-uptake blockers and drug seeking behavior (1994) (0)
399. Withdrawal from chronic cocaine in rats: A model of depression (1996) (0)
The ligand-selectivity of cloned human and rat opiate mu receptors studied with [125I]IOXY-AGO (1994) (0)
Preparation of Ring D Modified Analogues of Salvinorin A, A Kappa Opioid Agonist from Salvia divinorum (2006) (0)
Synthesis and Biological Activity of 3‐Substituted 3‐Desoxynaltrindole Derivatives. (1998) (0)
How p hysician Obesity s pecialists Use Drugs to t reat Obesity (2009) (0)
Enantiomers of diastereoisomeric cis-N-[1-(2-hydroxy-2-phenylethyl)-3-methyl-4-piperidyl]-N-phenylpropana mides: Synthesis, x-ray analysis, and biological activities (vol 38, pg 3652, 1995) (1996) (0)
Functional Correlates Of 5-HT1A Receptor Activation After Exposure To Repeated Cocaine Administration In Rats (1994) (0)
Chronic ICV infusion of morphine and NPFF down-regulate mu opioid receptors in rat brain: A quantitative autoradiographic study (1994) (0)
Differentiation of the neurobiological effects of amphetamine and amphetamine like stimulants (2013) (0)
A Case of Cigarette Smoking- Induced Acute Eosinophilic Pneumonia Showing Tolerance (2017) (0)
Synthesis and Opioid Receptor Activity of Salvinicin Analogues (2007) (0)
Pseudoirreversible binding of opiates to opioid receptor subtypes in rat brain: a quantitative study. (1990) (0)
Probes for narcotic receptor-mediated phenomena. 25. Synthesis and evaluation of N-alkyl-substituted (alpha-piperazinylbenzyl)benzamides as novel, highly selective delta opioid receptor agonists. (1997) (0)
Chapter 19. Dual dopamine/serotonin releasers as potential medications for stimulant and alcohol addictions (2008) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Richard Brian Rothman?

Richard Brian Rothman is affiliated with the following schools:

Richard Brian Rothman's Academic­Influence.com Rankings

Why Is Richard Brian Rothman Influential?

Richard Brian Rothman's Published Works

Published Works

What Schools Are Affiliated With Richard Brian Rothman?

Richard Brian Rothman's AcademicInfluence.com Rankings